| Bid | 4.33 |
| Market Cap | 90.28M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.95 |
| PE Ratio (ttm) | -0.73 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.36 |
| Volume | 21,301 |
| Avg. Volume (20D) | 224,500 |
| Open | 4.34 |
| Previous Close | 4.25 |
| Day's Range | 4.31 - 4.50 |
| 52-Week Range | 4.01 - 29.70 |
| Beta | undefined |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...
Analyst Forecast
According to 6 analyst ratings, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 533.64% from the latest price.
Next Earnings Release
Analysts project revenue of $100.00K, reflecting a n/a YoY growth and earnings per share of -1.38, making a -40.00% decrease YoY.
1 month ago · seekingalpha.com
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD PatientsAdverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS...
